GeoVax to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 and Provide Corporate Update
via NewMediaWire -- GeoVax Labs, Inc.
GOVX, GOVXW) (“GeoVax” or the “Company”), a biotechnology company
developing human immunotherapies and vaccines against infectious
diseases and cancer, announces today that it plans to report third
quarter 2020 financial results on Thursday, November 5, 2020 after
the market closes.
Management will host a conference call at 8:15
a.m. ET on Friday, November 6, 2020 to review financial results and
provide an update on corporate developments. Following
management’s formal remarks, there will be a question and answer
Participants are asked to pre-register for the
call via the following
Please note that registered participants will
receive their dial-in number upon registration and will dial
directly into the call without delay. Those without Internet
access or who are unable to pre-register may dial in by calling
1-866-777-2509 (domestic) or 1-412-317-5413 (international).
All callers should dial in approximately 10 minutes prior to the
scheduled start time and ask to be joined into the GeoVax Labs
The conference call will be available through a
live webcast found here:
A webcast replay of the call will be available
approximately one hour after the end of the call through February
6, 2021. The webcast replay can be accessed through the above
links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088
(international) and using access code 10149661. The telephonic
replay will be available until November 20, 2020.
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing human vaccines against infectious
diseases and cancer using a novel patented Modified Vaccinia
Ankara-Virus Like Particle (MVA-VLP) based vaccine platform.
On this platform, MVA, a large virus capable of carrying
several vaccine antigens, expresses proteins that assemble into VLP
immunogens within (in vivo) the person receiving the vaccine.
The production of VLPs in the person being vaccinated mimics
virus production in a natural infection, stimulating both the
humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP
derived vaccines elicit durable immune responses in the host
similar to a live-attenuated virus, while providing the safety
characteristics of a replication-defective vector.
GeoVax’s current development programs are focused
on preventive vaccines against COVID-19, HIV, Zika Virus,
hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and
malaria, as well as therapeutic vaccines against multiple cancers.
The Company has designed a preventive HIV vaccine candidate to
fight against the subtype of HIV prevalent in the commercial
markets of the Americas, Western Europe, Japan, and Australia.
Human clinical trials for this program are managed by the HIV
Vaccine Trials Network (HVTN) with the support of the National
Institutes of Health (NIH). GeoVax’s HIV vaccine candidate is
also part of two separate collaborative efforts to apply its
innovative gene therapy approach toward a functional cure for
Cautionary Note Regarding Forward-Looking
This release contains forward-looking statements
regarding the timing of the release of GeoVax’s financial results
and earnings conference call and the earnings release and call are
expected to discuss forward-looking statements regarding GeoVax’s
ability to implement its business plan, expected revenues and
future success. The words “believe,” “may,” “estimate,” “continue,”
“anticipate,” “intend,” “should,” “plan,” “could,” “target,”
“potential,” “is likely,” “will,” “expect” and similar expressions,
as they relate to us, are intended to identify forward-looking
statements. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends that we believe may affect our financial
condition, results of operations, business strategy and financial
needs. Actual results may differ materially from those
included in these statements due to a variety of factors, including
whether: GeoVax can develop and manufacture its vaccines with the
desired characteristics in a timely manner, GeoVax’s vaccines will
be safe for human use, GeoVax’s vaccines will effectively prevent
targeted infections in humans, GeoVax’s vaccines will receive
regulatory approvals necessary to be licensed and marketed, GeoVax
raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or
easier to use than GeoVax’s products, GeoVax will be able to enter
into favorable manufacturing and distribution agreements, the
impact of the COVID-19 pandemic continues, and other factors, over
which GeoVax has no control.
Further information on our risk factors is
contained in our registration statement on Form S-1 (File No.
333-239958) that we have filed with the SEC and the final
prospectus. Any forward-looking statement made by us herein
speaks only as of the date on which it is made. Factors or events
that could cause our actual results to differ may emerge from time
to time, and it is not possible for us to predict all of them. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by law.